The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Mutations in the p53 gene occur in diverse human tumour types
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The development of PCR‐associated molecular diagnostics empowered the description of the first p53 mutations in colon and lung cancer in 1989, and such mutations were rapidly found to be common in other types of cancer [76, 77, 78].”
From The TP53 tumor suppressor gene: From molecular biology to clinical investigations (2025) · cites this paper as [77]
In the citing paper
“In tumor cells the TP53 gene is often mutated or lost due to chromosome 17 deletion, whereas in normal cells the gene is intact.19,20”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase
Saiki, R. K., Gelfand, D. H., Stoffel, S., Scharf, S. J., Higuchi, R., Horn, G. T., Mullis, K. B., & Erlich, H. A. (1988) · Science · doi:10.1126/science.2448875 · Cited by 17,719
T antigen is bound to a host protein in SY40-transformed cells
LANE, D. P., & CRAWFORD, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,394
Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas
Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., et al. (1989) · Science · doi:10.1126/science.2649981 · Cited by 2,066
Self-citationThe p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987
Linzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,813
λ ZAP: a bacteriophage λ expression vector with in vivo excision properties
Short, J. M., Fernandez, J. M., Sorge, J. A., & Huse, W. D. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.15.7583 · Cited by 1,365
Hereditary cancer, oncogenes, and antioncogenes.
Knudson, A. G. (1985) · PubMed · Cited by 1,218
Functional inactivation of genes by dominant negative mutations
Herskowitz, I. (1987) · Nature · doi:10.1038/329219a0 · Cited by 1,160
Finlay, C. A., Hinds, P. W., Tan, T. H., Eliyahu, D., Oren, M., & Levine, A. J. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.2.531 · Cited by 1,144
Rearrangement of the p53 gene in human osteogenic sarcomas.
Masuda, H., Miller, C., Koeffler, H. P., Battifora, H., & Cline, M. J. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7716 · Cited by 474
Cited by
Items 101–175 of 175
Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer
Barton, C., Staddon, S., Hughes, C., Hall, P., O'Sullivan, C., Klöppel, G., Theis, B., Russell, R., Neoptolemos, J., & Williamson, R. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.467 · Cited by 376
Santhanam, U., Ray, A., & Sehgal, P. B. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.17.7605 · Cited by 375
Inhibition of DNA replication factor RPA by p53
Dutta, A., Ruppert, J. M., Aster, J. C., & Winchester, E. (1993) · Nature · doi:10.1038/365079a0 · Cited by 374
Two New p73 Splice Variants, γ and δ, with Different Transcriptional Activity
De Laurenzi, V., Costanzo, A., Barcaroli, D., Terrinoni, A., Falco, M., Annicchiarico-Petruzzelli, M., Levrero, M., & Melino, G. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.9.1763 · Cited by 368
Bargonetti, J., Friedman, P. N., Kern, S. E., Vogelstein, B., & Prives, C. (1991) · Cell · doi:10.1016/0092-8674(91)90560-l · Cited by 367
Self-citationMietz, J. A., Unger, T., Huibregtse, J. M., & Howley, P. M. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05608.x · Cited by 365
Shaulsky, G., Goldfinger, N., Ben-Ze'ev, A., & Rotter, V (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.12.6565 · Cited by 356
Toward the Primary Prevention of Cancer
Henderson, B. E., Ross, R. K., & Pike, M. C. (1991) · Science · doi:10.1126/science.1957166 · Cited by 355
Multifactorial analysis of p53 alteration in human cancer: A review
Soussi, T., Legros, Y., Lubin, R., Ory, K., & Schlichtholz, B. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910570102 · Cited by 353
Osteoblasts are target cells for transformation in c-fos transgenic mice
Grigoriadis, A., Schellander, K., Wang, Z., & Wagner, E. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.3.685 · Cited by 350
(1992) · American Journal of Otolaryngology · doi:10.1016/0196-0709(92)90038-u · Cited by 350
p53, cancer and the immune response
Blagih, J., Buck, M. D., & Vousden, K. H. (2020) · Journal of Cell Science · doi:10.1242/jcs.237453 · Cited by 333
Analysis of Loss of Heterozygosity in 399 Premalignant Breast Lesions at 15 Genetic Loci
O'Connell, P., Pekkel, V., Allred, D. C., Fuqua, S. A. W., Osborne, C. K., & Clark, G. M. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.9.697 · Cited by 340
A role for p53 in base excision repair
Zhou, J. (2001) · The EMBO Journal · doi:10.1093/emboj/20.4.914 · Cited by 333
Donehower, L. A., & Bradley, A. (1993) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(93)90004-v · Cited by 333
The p53 Tumor Suppressor Gene: From Molecular Biology to Clinical Investigation
SOUSSI, T. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06705.x · Cited by 332
Midgley, C. A., Fisher, C. J., Bártek, J., Vojtések, B., Lane, D., & Barnes, D. M. (1992) · Journal of Cell Science · doi:10.1242/jcs.101.1.183 · Cited by 330
Selective Evolution of Stromal Mesenchyme with p53 Loss in Response to Epithelial Tumorigenesis
Hill, R., Song, Y., Cardiff, R. D., & Van Dyke, T. (2005) · Cell · doi:10.1016/j.cell.2005.09.030 · Cited by 324
Jones, P. A. (2002) · Oncogene · doi:10.1038/sj.onc.1205597 · Cited by 321
Cytogenetics of papillary renal cell tumors
Kovacs, G., Fuzesi, L., Emanuel, A., & Kung, H. (1991) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.2870030403 · Cited by 320
Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines.
Cheng, J., & Haas, M. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.10.5502 · Cited by 316
Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90.
Blagosklonny, M. V., Toretsky, J., Bohen, S., & Neckers, L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8379 · Cited by 314
Zambetti, G. P., Bargonetti, J., Walker, K., Prives, C., & Levine, A. J. (1992) · Genes & Development · doi:10.1101/gad.6.7.1143 · Cited by 311
EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins.
Szekely, L., Selivanova, G., Magnusson, K. P., Klein, G., & Wiman, K. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.12.5455 · Cited by 309
Crook, T., Wrede, D., Tidy, J. A., Vousden, K. H., Wrede, D., Tidy, J., Mason, W. P., & Evans, D. J. (1992) · The Lancet · doi:10.1016/0140-6736(92)90662-m · Cited by 309
Van Meir, E. G., Polverini, P. J., Chazin, V. R., Su Huang, H.-J., de Tribolet, N., & Cavenee, W. K. (1994) · Nature Genetics · doi:10.1038/ng1094-171 · Cited by 307
Prevalence and Spectrum of Germline Mutations of the p53 Gene among Patients with Sarcoma
Toguchida, J., Yamaguchi, T., Dayton, S. H., Beaughamp, R. L., Herrera, G. E., Ishizaki, K., Yamamuro, T., Meyers, P. A., Little, J. B., Sasaki, M. S., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262001 · Cited by 307
Role of Cysteine Residues in Regulation of p53 Function
Rainwater, R., Parks, D., Anderson, M. E., Tegtmeyer, P., & Mann, K. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.7.3892 · Cited by 306
Gasparini, G., Weidner, N., Maluta, S., Pozza, F., Boracchi, P., Mezzetti, M., Testolin, A., & Bevilacqua, P. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910550507 · Cited by 305
Moser, A. R., Dove, W. F., Roth, K. A., & Gordon, J. I. (1992) · The Journal of cell biology · doi:10.1083/jcb.116.6.1517 · Cited by 304
Targeting p53 as a general tumor antigen.
Theobald, M., Biggs, J., Dittmer, D., Levine, A. J., & Sherman, L. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.26.11993 · Cited by 304
p53 oncogene mutations in three human prostate cancer cell lines
Carroll, A. G., Voeller, H. J., Sugars, L., & Gelmann, E. P. (1993) · The Prostate · doi:10.1002/pros.2990230206 · Cited by 303
Lang, F. F., Miller, D. C., Koslow, M., & Newcomb, E. W. (1994) · Journal of Neurosurgery · doi:10.3171/jns.1994.81.3.0427 · Cited by 300
Sex steroidal regulation of uterine leiomyoma growth and apoptosis
Maruo, T. (2004) · Human Reproduction Update · doi:10.1093/humupd/dmh019 · Cited by 294
p53 gene mutations and protein accumulation in human ovarian cancer.
Kupryjańczyk, J., Thor, A. D., Beauchamp, R., Merritt, V, Edgerton, S. M., Bell, D. A., & Yandell, D. W. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.11.4961 · Cited by 289
Allele loss on chromosome 16 associated with progression of human hepatocellular carcinoma.
Tsuda, H., Zhang, W. D., Shimosato, Y., Yokota, J., Terada, M., Sugimura, T., Miyamura, T., & Hirohashi, S. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.17.6791 · Cited by 289
Genetic background alters the spectrum of tumors that develop in p53‐deficient mice
Harvey, M., McArthur, M. J., Montgomery, C. A., Bradley, A., & Donehower, L. A. (1993) · The FASEB Journal · doi:10.1096/fasebj.7.10.8344491 · Cited by 285
Genetic basis for p53 overexpression in human breast cancer.
Davidoff, A. M., Humphrey, P. A., Iglehart, J. D., & Marks, J. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.11.5006 · Cited by 285
Tumor Suppressor p53 Protein Is a New Target for the Metastasis-associated Mts1/S100A4 Protein
Grigorian, M., Andresen, S., Tulchinsky, E., Kriajevska, M., Carlberg, C., Kruse, C., Cohn, M., Ambartsumian, N., Christensen, A., Selivanova, G., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010231200 · Cited by 282
Neoplastic progression in ulcerative colitis: Histology, DNA content, and loss of a p53 allele
Burmer, G. C., Rabinovitch, P. S., Haggitt, R. C., Crispin, D. A., Brentnall, T. A., Kolli, V. R., Stevens, A. C., & Rubin, C. E. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)91184-6 · Cited by 280
Dumaz, N., Drougard, C., Sarasin, A., & Daya-Grosjean, L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.22.10529 · Cited by 279
The p53 tumour suppressor protein is phosphorylated at serine 389 by casein kinase II.
Meek, D. W., Simon, S., Kikkawa, U., & Eckhart, W. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07524.x · Cited by 277
Bártek, J., Bártková, J., Vojtěšek, B., Stašková, Z., Rejthar, A., Kovařík, J., & Lane, D. P. (1990) · International Journal of Cancer · doi:10.1002/ijc.2910460515 · Cited by 276
Mutations of the p53 Gene as a Prognostic Factor in Aggressive B-Cell Lymphoma
Ichikawa, A., Kinoshita, T., Watanabe, T., Kato, H., Nagai, H., Tsushita, K., Saito, H., & Hotta, T. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708213370804 · Cited by 274
Lechner, M. S., Mack, D. H., Finicle, A. B., Crook, T., Vousden, K. H., & Laimins, L. A. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05375.x · Cited by 273
Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers.
Davidoff, A. M., Iglehart, J. D., & Marks, J. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.8.3439 · Cited by 272
Genetic diagnosis of lymph-node metastasis in colorectal cancer
Hayashi, N., Ito, I., Nakamura, Y., Yanagisawa, A., Kato, Y., Nakamori, S., Imaoka, S., Watanabe, H., Hayashi, N., Ogawa, M., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90922-2 · Cited by 272
Mechanisms of p53 loss in human sarcomas.
Mulligan, L. M., Matlashewski, G. J., Scrable, H. J., & Cavenee, W. K. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.15.5863 · Cited by 269
Mutant p53: an oncogenic transcription factor
Strano, S., Dell'Orso, S., Di Agostino, S., Fontemaggi, G., Sacchi, A., & Blandino, G. (2007) · Oncogene · doi:10.1038/sj.onc.1210296 · Cited by 269
Differential expression of epidermal growth factor-related proteins in human colorectal tumors.
Ciardiello, F., Kim, N., Saeki, T., Dono, R., Persico, M. G., Plowman, G. D., Garrigues, J., Radke, S., Todaro, G. J., & Salomon, D. S. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.17.7792 · Cited by 267
Harrington, E. A., Fanidi, A., & Evan, G. I. (1994) · Current Opinion in Genetics & Development · doi:10.1016/0959-437x(94)90100-7 · Cited by 265
Jaros, E., Perry, R., Adam, L., Kelly, P., Crawford, P., Kalbag, R., Mendelow, A., Sengupta, R., & Pearson, A. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.273 · Cited by 264
Sandberg, A. A., & Bridge, J. A. (2003) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(03)00105-5 · Cited by 262
Houbiers, J. G. A., Nijman, H. W., Van Der Burg, S. H., Drijfhout, J. W., Kenemans, P., Van De Velde, C. J. H., Brand, A., Momburg, F., Kast, W. M., & Melief, C. J. M. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230905 · Cited by 258
Osborne, C., Wilson, P., & Tripathy, D. (2004) · The Oncologist · doi:10.1634/theoncologist.9-4-361 · Cited by 257
Smoking, p53 Mutation, and Lung Cancer
Gibbons, D. L., Byers, L. A., & Kurie, J. M. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0539 · Cited by 255
Fries, K. L., Miller, W. E., & Raab-Traub, N. (1996) · Journal of Virology · doi:10.1128/jvi.70.12.8653-8659.1996 · Cited by 255
Li, P.-X., Wong, J., Ayed, A., Ngo, D., Brade, A. M., Arrowsmith, C., Austin, R. C., & Klamut, H. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m909580199 · Cited by 254
p53 is frequently mutated in Burkitt's lymphoma cell lines
Farrell, P. J., Allan, G. J., Shanahan, F., Vousden, K. H., & Crook, T. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb07837.x · Cited by 254
(1994) · PubMed · Cited by 244
Overexpression of VEGF and Angiopoietin 2: A Key to High Vascularity of Hepatocellular Carcinoma?
Moon, W. S., Rhyu, K. H., Kang, M. J., Lee, D. G., Yu, H. C., Yeum, J. H., Koh, G. Y., & Tarnawski, A. S. (2003) · Modern Pathology · doi:10.1097/01.mp.0000071841.17900.69 · Cited by 210
G1 and G2 cell-cycle arrest following microtubule depolymerization in human breast cancer cells
Blajeski, A. L., Phan, V. A., Kottke, T. J., & Kaufmann, S. H. (2002) · Journal of Clinical Investigation · doi:10.1172/jci13275 · Cited by 200
Manganese superoxide dismutase regulation and cancer
Dhar, S. K., & St. Clair, D. K. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.03.009 · Cited by 196
Death receptors as targets in cancer
Micheau, O., Shirley, S., & Dufour, F. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12238 · Cited by 189
The many faces of p53: something for everyone
Levine, A. J. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz026 · Cited by 163
Saleh, M. N., Patel, M. R., Bauer, T. M., Goel, S., Falchook, G. S., Shapiro, G. I., Chung, K. Y., Infante, J. R., Conry, R. M., Rabinowits, G., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0715 · Cited by 159
p53 Mutations in sporadic adrenocortical tumors
Ohgaki, H., Kleihues, P., & Heitz, P. U. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910540310 · Cited by 139
Elevated c-Src tyrosine kinase activity in premalignant epithelia of ulcerative colitis.
Cartwright, C. A., Coad, C. A., & Egbert, B. M. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117000 · Cited by 134
Levine, A. J., Jenkins, N. A., & Copeland, N. G. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.11.009 · Cited by 121
Restoration of Telomeres in Human Papillomavirus-Immortalized Human Anogenital Epithelial Cells
Klingelhutz, A. J., Barber, S. A., Smith, P. P., Dyer, K., & McDougall, J. K. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.2.961 · Cited by 86
Small molecule modulators of protein-protein interactions: selected case studies
Aeluri, M., Chamakuri, S., Dasari, B., Guduru, S. K. R., Jimmidi, R., Jogula, S., & Arya, P. (2014) · Chemical Reviews · doi:10.1021/cr4004049 · Cited by 79
Shin, T. H., Paterson, A. J., & Kudlow, J. E. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.9.4694 · Cited by 78
p53 protein accumulation and gene mutations in human glioma cell lines
Anker, L., Ohgaki, H., Ludeke, B. I., Herrmann, H., Kleihues, P., & Westphal, M. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910550618 · Cited by 66
The TP53 tumor suppressor gene: From molecular biology to clinical investigations
Baliakas, P., & Soussi, T. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20106 · Cited by 50
(1999) · doi:10.1002/(sici)1098-1004(1999)14:1
Metadata
- Authors
- Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hosteller, R., Cleary, K., Signer, S. H., Davidson, N., Baylin, S., Devilee, P., Glover, T., Collins, F. S., Weslon, A., Modali, R., Harris, C. C., & Vogelstein, B.
- Venue
- Nature
- Published
- 1989-12
- Volume
- 342
- Issue
- 6250
- Pages
- 705-708
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2054549064
- Cited by
- 2,733
- References
- 20
- FWCI
- 76.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.